Enhanced coordinated specialty care (CSC 2.0) for first-episode psychosis
Official title: Randomized controlled trial of enhanced coordinated specialty care (CSC 2.0)
Funded at Mclean Hospital · NIH-11419754 · Data updated 2026-11-12
A large multi-clinic study tests a boosted version of coordinated specialty care to help people experiencing a first episode of psychosis stay in treatment and improve outcomes.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mclean Hospital NIH-funded |
| Lab location | 1 site (Belmont, United States) |
| Project start | May 15, 2019 |
| Project end | June 30, 2028 |
| Funding year | 2026 |
| Award (this year) | $1,050,584 |
| NIH project number | 5P50MH115846-08 |
| Project ID | NIH-11419754 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults experiencing a first episode of psychosis who are receiving coordinated specialty care in participating Massachusetts clinics.
✕Less likely to help
Patients at clinics outside the study sites or those not receiving CSC may not directly benefit.
What this research studies
This project tests CSC 2.0, a richer, hub-and-spoke approach that adds peer providers, digital outreach, family groups, better coordination with emergency and primary care, and cognitive remediation to standard CSC. It is designed as a cluster-randomized trial across multiple Massachusetts clinics to see if the enhanced program improves engagement and long-term outcomes compared with real-world CSC. Researchers will measure treatment retention, symptom and functioning outcomes, and adherence across sites over several years. The study uses a centralized hub to coordinate services and ensure fidelity to the CSC model, addressing real-world barriers identified by clinics. If successful, CSC 2.0 could offer a scalable way to deliver more effective early intervention for psychosis in diverse clinical settings.
Why it matters
Potential benefit: If CSC 2.0 proves effective, patients with first-episode psychosis could experience better engagement in care and improved recovery outcomes.
How similar studies have gone: Previous CSC research supports early intervention, but real-world implementation often falls short; this trial tests improvements to close that gap.
Where this research is happening
-
Mclean Hospital
Belmont, United States Active
Researchers
- Principal investigator: Ongur, Dost — Mclean Hospital
- Study coordinator: Ongur, Dost
Related research
Other NIH-funded projects on the same topics.
-
Cognitive behavioral therapy and trazodone for insomnia phenotypes with high blood pressure
A clinical study tests how CBT-I and the sleep drug trazodone work for adults with insomnia and high blood pressure, focusing on a specific sleep duration pattern.
-
Shorter antifungal treatment for kids with candidemia
A multi-center pediatric trial tests whether a shorter, 7 extra days of antifungal therapy after an initial 7 days is just as good as the standard 14-day approach for kids with candidemia who are improving on echinocandin therapy.
-
Short Course vs Standard Course Antifungal Therapy for Pediatric Candidemia
This study tests whether a shorter 7-day total antifungal treatment after an initial 7 days of echinocandin therapy is as effective as the usual 14-day course for children with candidemia.
-
Shorter antifungal treatment for kids with candidemia
A multi-center study tests whether kids with candidemia can finish treatment earlier after an initial week of antifungal therapy than the standard two weeks total.
-
Shorter antifungal treatment for kids with candidemia
This study tests whether children with candidemia can finish treatment after 7 days of an echinocandin if they are improving, instead of completing a full 14 days.
-
Shorter antifungal course for kids with candidemia
A multi-center study tests whether 7 extra days of antifungal therapy after an initial week of treatment can be shortened safely for children with candidemia.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.